Compare Amylx Pharmaceuticals Inc (AMLX) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Amylx Pharmaceuticals Inc trades at $23.63 (market cap $2.64B), while SiTime Corporation trades at $700 (market cap $20.05B). The key difference: SiTime Corporation is far larger — about 7.6× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, SiTime Corporation nearer its low. Which is the better fit depends on your goals.
| AMLX | SITM | |
|---|---|---|
Market Cap | $2.64B | $20.05B |
Sector | Health | Technology |
52-Week High | $24.19 | $901.60 |
52-Week Low | $7.82 | $212.77 |
Enterprise Value | $2.39B | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
SiTime Corporation (SITM) trades at $697.50, up 1.09% with strong bullish technical signals and consistent earnings beats. The stock shows robust revenue growth, expanding margins, and positive analyst sentiment with a $870 consensus price target. Recent Q2 2026 results exceeded expectations with 127% revenue growth, driven by AI infrastructure demand and the Renesas acquisition.
Outlook remains positive with AI timing growth as the key catalyst, though premium valuation and integration risks warrant caution. The stock offers significant upside potential from current levels but faces execution risks in scaling operations and maintaining margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
